Drug intelligence / Profile preview

RT401 + RT402

Development stage: Preclinical
Lead developer: Royaltechmed
Modality: Oncolytic Viruses → Oncolytic Therapeutics

Overview

RT401 + RT402 is a combination oncolytic virus therapy currently in preclinical development by Royaltechmed. Part of the company's oncolytic virus platform, this candidate is being investigated for the treatment of solid tumors, including liver cancer, lung cancer, and prostate cancer. The therapy is designed to utilize the natural ability of certain viruses to selectively infect and replicate within malignant cells, leading to direct oncolysis and the subsequent induction of a robust, systemic anti-tumor immune response through the release of tumor antigens and inflammatory cytokines.

Other names: RT401~RT402

Beyond the preview

Go deeper on RT401 + RT402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RT401 + RT402.

Explore the full profile